Prøve GULL - Gratis

Why are strategic partnerships critical for life science innovation?

BioSpectrum Asia

|

BioSpectrum Asia July 2024

Strategic alliances between startups and large companies will be more and more important as the life science sector develops because they will spur research and expedite the release of breakthrough treatments for patients. Innovation stays at the forefront of the industry thanks to the cooperative efforts of resource-rich businesses and nimble startups, which ultimately benefit patients and improve global health outcomes.

Why are strategic partnerships critical for life science innovation?

Strategic partnerships between life science startups and large corporations are becoming increasingly vital for accelerating innovation and bringing new therapies to market. These collaborations provide a symbiotic relationship where startups gain access to resources, expertise, and infrastructure, while large companies tap into cutting-edge research and innovative ideas.

Benefits for startups

For early-stage life science startups, strategic partnerships with large companies can be a game-changer. These collaborations provide access to resources that would otherwise be out of reach, such as:

Expertise for Various Stages in the Commercialisation Process:

Navigating the complex landscape of regulatory affairs, clinical trials, and large-scale manufacturing can be daunting for startups. Large companies typically have established regulatory teams and streamlined processes that can significantly aid startups in obtaining necessary approvals and conducting comprehensive clinical trials. Additionally, large-scale manufacturing facilities and expertise ensure that startups can scale their innovations effectively. Access to this expertise can help startups overcome regulatory hurdles, design, and execute clinical trials more efficiently, and transition from small-scale production to mass manufacturing seamlessly.

Funding and Financial Support:

Securing sufficient funding is one of the most significant challenges for early-stage startups. Strategic partnerships often come with financial investments that can propel research and development efforts forward. This support can be crucial for startups, enabling them to focus on innovation without the constant pressure of financial constraints. Funding from large companies not only provides the necessary capital but also adds credibility to the startup, making it easier to attract additional investors and resources.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Listen

Translate

Share

-
+

Change font size